Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study

1993 ◽  
Vol 37 (5) ◽  
pp. 307-315 ◽  
Author(s):  
Albrecht Lindemann ◽  
Peter Brossart ◽  
Klaus H�ffken ◽  
Michael Fla�hove ◽  
Dimitris Voliotis ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Low Dose ◽  
Interleukin 2 ◽  
Immunomodulatory Effects ◽  
Phase Ib

Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients

2001 ◽  
Vol 78 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Katia Cerea ◽  
Fabrizio Romano ◽  
Andrea Ferrari Bravo ◽  
Vittorio Motta ◽  
Fabio Uggeri ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Low Dose ◽  
Interleukin 2 ◽  
Phase Ib ◽  
Preoperative Administration ◽  
Gastric Cancer Patients

Immunoendocrine Therapy with Interleukin-2 (IL-2) and Medroxyprogesterone Acetate (MPA): A Randomized Study with or without MPA in Metastatic Renal Cancer Patients during IL-2 Maintenance Treatment after Response or Stable Disease to IL-2 Subcutaneous Therapy

1993 ◽  
Vol 79 (4) ◽  
pp. 246-249 ◽  
Author(s):  
Paolo Lissoni ◽  
Sandro Barni ◽  
Gabriele Tancini ◽  
Fernando Brivio ◽  
Paolo Cardellini ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Cancer Patients ◽  
Renal Cancer ◽  
Stable Disease ◽  
Medroxyprogesterone Acetate ◽  
Low Dose ◽  
Interleukin 2 ◽  
Cytotoxic Lymphocytes ◽  
Metastatic Renal Cancer ◽  
Significant Difference

Aims and Background It is known that interleukin-2 (IL-2) activated cytotoxic lymphocytes require a cell-cell contact to exert their anticancer action. Therefore, the pronounced fibrosis that generally characterizes the neoplastic mass could counteract the action of cytotoxic lymphocytes. Some preliminary studies have shown that progesterone and its analogs may inhibit fibroblast proliferation. On the basis of such evidence, we have designed a clinical study with or without the progestational agent medroxyprogesterone acetate (MPA) in metastatic renal cancer patients in maintenance therapy with IL-2 following response or stable disease (SD) after two cycles of IL-2 subcutaneous immunotherapy, in an attempt to evaluate the influence of MPA on free-from progression (FPP) period. Methods The study included 30 consecutive patients who were randomized to receive IL-2 alone (3 mllion IU twice/day for 5 days/month subcutaneously) or IL-2 plus low-dose MPA (500 mg orally one day/week) without interruption until disease progression. Results A FPP period longer than 1 year was obtained in 8/14 patients treated with IL-2 plus MPA and in only 3/16 patients treated with IL-2 alone. The difference was statistically significant. On the contrary, no significant difference was seen in the mean number of lymphocytes and eosinophils, which was evaluated monthly. Finally, no hyperglycemic or thromboembolic complications occurred in patients concomitantly treated with MPA. Conclusions This preliminary study would suggest that the concomitant administration of low-dose MPA may prolonge the FFP period in metastatic renal cancer patients under maintenance therapy with IL-2. A longer follow-up will be required to evaluate the influence of MPA on overall survival.

scholarly journals Effects of interleukin-2 in immunostimulation and immunosuppression

2019 ◽  
Vol 217 (1) ◽  
Author(s):  
Jonathan G. Pol ◽  
Pamela Caudana ◽  
Juliette Paillet ◽  
Eliane Piaggio ◽  
Guido Kroemer
Keyword(s):  
T Cells ◽  
Low Dose ◽  
Expression Patterns ◽  
Interleukin 2 ◽  
Effector T Cells ◽  
High Dose ◽  
Immunomodulatory Effects ◽  
Innovative Strategies ◽  
Spatiotemporal Expression ◽  
Clinical Responses

Historically, interleukin-2 (IL-2) was first described as an immunostimulatory factor that supports the expansion of activated effector T cells. A layer of sophistication arose when regulatory CD4+ T lymphocytes (Tregs) were shown to require IL-2 for their development, homeostasis, and immunosuppressive functions. Fundamental distinctions in the nature and spatiotemporal expression patterns of IL-2 receptor subunits on naive/memory/effector T cells versus Tregs are now being exploited to manipulate the immunomodulatory effects of IL-2 for therapeutic purposes. Although high-dose IL-2 administration has yielded discrete clinical responses, low-dose IL-2 as well as innovative strategies based on IL-2 derivatives, including “muteins,” immunocomplexes, and immunocytokines, are being explored to therapeutically enhance or inhibit the immune response.

Cancer patients' lymphocytes contain CD3+CD4+cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells

1989 ◽  
Vol 30 (4) ◽  
pp. 233-238 ◽  
Author(s):  
Marina Radrizzani ◽  
Michele Quaia ◽  
Barbara Benedetti ◽  
Salvatore Andreola ◽  
Maurizio Vaglini ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Tumor Cells ◽  
Low Dose ◽  
Interleukin 2 ◽  
Autologous Tumor ◽  
Cd4 Cells ◽  
Accessory Cells
Sign in / Sign up

Export Citation Format

Share Document